{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:19:25Z","timestamp":1794352765580,"version":"4.9.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jns.2021.120078","type":"journal-article","created":{"date-parts":[[2021,12,4]],"date-time":"2021-12-04T10:16:14Z","timestamp":1638612974000},"page":"120078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan"],"prefix":"10.1016","volume":"432","author":[{"given":"Makio","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsoo","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kajimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihisa","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jns.2021.120078_bb0005","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1474-4422(11)70067-9","article-title":"Postural deformities in Parkinson\u2019s disease","volume":"10","author":"Doherty","year":"2011","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.jns.2021.120078_bb0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/mdc3.12810","article-title":"Postural abnormalities in Parkinson's disease: an epidemiological and clinical multicenter study","volume":"6","author":"Tinazzi","year":"2019","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"11","key":"10.1016\/j.jns.2021.120078_bb0015","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/mds.21058","article-title":"Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy","volume":"21","author":"Ashour","year":"2006","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.jns.2021.120078_bb0020","first-page":"75","article-title":"Camptocormia in Parkinson\u2019s disease: definition, epidemiology, pathogenesis and treatment modalities","volume":"87","author":"Srivanitchapoom","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"11","key":"10.1016\/j.jns.2021.120078_bb0025","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1136\/jnnp.2006.087908","article-title":"Parkinson\u2019s disease with camptocormia","volume":"77","author":"Bloch","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2021.120078_bb0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jns.2017.04.025","article-title":"Can postural abnormality really respond to levodopa in Parkinson's disease?","volume":"377","author":"Kataoka","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"3","key":"10.1016\/j.jns.2021.120078_bb0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.parkreldis.2012.09.008","article-title":"Long-term effect of repeated lidocaine injections into the external oblique for upper camptocormia in Parkinson\u2019s disease","volume":"19","author":"Furusawa","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120078_bb0040","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.parkreldis.2018.12.002","article-title":"Use of botulinum toxin in Parkinson's disease","volume":"59","author":"Jocson","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.120078_bb0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00023210-200216030-00003","article-title":"Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management","volume":"16","author":"Suzuki","year":"2002","journal-title":"CNS Drugs."},{"issue":"6","key":"10.1016\/j.jns.2021.120078_bb0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/WNF.0000000000000416","article-title":"Quetiapine relieved Pisa syndrome in patient with Parkinson disease","volume":"43","author":"Zhao","year":"2020","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2021.120078_bb0055","article-title":"Camptocormia in Parkinson\u2019s disease","volume":"2010","author":"Abe","year":"2010","journal-title":"Parkinson\u2019s Dis."},{"issue":"10","key":"10.1016\/j.jns.2021.120078_bb0060","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/14656566.7.10.1399","article-title":"The levodopa wearing-off phenomenon in Parkinson\u2019s disease: pharmacokinetic considerations","volume":"7","author":"Stocchi","year":"2006","journal-title":"Expert. Opin. Pharmacother."},{"issue":"Pt 5","key":"10.1016\/j.jns.2021.120078_bb0065","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/brain\/awh128","article-title":"Increased adenosine A2A receptors in the brain of Parkinson\u2019s disease patients with dyskinesias","volume":"127","author":"Calon","year":"2004","journal-title":"Brain."},{"issue":"2","key":"10.1016\/j.jns.2021.120078_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017338","article-title":"Adenosine A2A receptors measured with [11C]TMSX PET in the striata of Parkinson\u2019s disease patients","volume":"6","author":"Mishina","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jns.2021.120078_bb0075","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrd3955","article-title":"Adenosine receptors as drug targets\u2014what are the challenges?","volume":"12","author":"Chen","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.jns.2021.120078_bb0080","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A2A receptors in Parkinson\u2019s disease","volume":"29","author":"Schwarzschild","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.jns.2021.120078_bb0085","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.parkreldis.2020.09.025","article-title":"How do adenosine A2A receptors regulate motor function?","volume":"80","author":"Mori","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120078_bb0090","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.parkreldis.2020.09.026","article-title":"Can adenosine A2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson\u2019s disease?","volume":"80","author":"Kanda","year":"2020","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2021.120078_bb0095","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14737175.2021.1880896","article-title":"Istradefylline \u2013 a first generation adenosine A2A antagonist for the treatment of Parkinson\u2019s disease","volume":"21","author":"Jenner","year":"2021","journal-title":"Expert. Rev. Neurother."},{"issue":"3","key":"10.1016\/j.jns.2021.120078_bb0100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.nbd.2010.03.003","article-title":"Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia","volume":"38","author":"Napolitano","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2021.120078_bb0105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2017.12.027","article-title":"Could istradefylline be a treatment option for postural abnormalities in mid-stage Parkinson\u2019s disease?","volume":"385","author":"Suzuki","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"15","key":"10.1016\/j.jns.2021.120078_bb0110","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/14656566.2018.1518433","article-title":"Safety and effectiveness of istradefylline in patients with Parkinson\u2019s disease: interim analysis of a post-marketing surveillance study in Japan","volume":"19","author":"Takahashi","year":"2018","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2021.120078_bb0115","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jns.2018.03.020","article-title":"Does istradefylline really have a dystonic mechanism?","volume":"388","author":"Kataoka","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.jns.2021.120078_bb0120","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5603\/PJNNS.a2019.0036","article-title":"A new therapeutic strategy with istradefylline for postural deformities in Parkinson\u2019s disease","volume":"53","author":"Fujioka","year":"2019","journal-title":"Neurol. Neurochir. Pol."},{"issue":"3","key":"10.1016\/j.jns.2021.120078_bb0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10377","article-title":"Rating scales for dystonia: a multicenter assessment","volume":"18","author":"Comella","year":"2003","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.jns.2021.120078_bb0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/mds.20213","article-title":"Movement Disorder Society task force report on the Hoehn and Yahr staging scale: status and recommendations","volume":"19","author":"Goetz","year":"2004","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.jns.2021.120078_bb0135","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1532-5415.1992.tb01992.x","article-title":"The mini-mental state examination: a comprehensive review","volume":"40","author":"Tombaugh","year":"1992","journal-title":"J. Am. Geriatr. Soc."},{"issue":"15","key":"10.1016\/j.jns.2021.120078_bb0140","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov. Disord."},{"issue":"3","key":"10.1016\/j.jns.2021.120078_bb0145","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1353-8020(99)00062-0","article-title":"Construction of freezing of gait questionnaire for patients with Parkinsonism","volume":"6","author":"Giladi","year":"2000","journal-title":"Parkinsonism Relat. Disord."},{"issue":"6","key":"10.1016\/j.jns.2021.120078_bb0150","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/08870449708406741","article-title":"The PDQ-8: development and validation of a short-form parkinson\u2019s disease questionnaire","volume":"12","author":"Jenkinson","year":"1997","journal-title":"Psychol. Health"},{"issue":"7","key":"10.1016\/j.jns.2021.120078_bb0155","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jns.2021.120078_bb0160","author":"Japanese MedDRA"},{"key":"10.1016\/j.jns.2021.120078_bb0165","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.nbd.2017.08.007","article-title":"Abnormal striatal plasticity in a DYT11\/SGCE myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition","volume":"10","author":"Maltese","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jns.2021.120078_bb0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-662-44519-8_8","article-title":"Great expectations: the placebo effect in Parkinson\u2019s disease","volume":"225","author":"Lidstone","year":"2014","journal-title":"Handb. Exp. Pharmacol."},{"issue":"3","key":"10.1016\/j.jns.2021.120078_bb0175","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.54.3.710","article-title":"Objective changes in motor function during placebo treatment in PD","volume":"54","author":"Goetz","year":"2000","journal-title":"Neurology."},{"issue":"8","key":"10.1016\/j.jns.2021.120078_bb0180","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/mds.28095","article-title":"A pooled analysis from phase 2b and 3 studies in Japan of istradefylline in Parkinson\u2019s disease","volume":"35","author":"Hattori","year":"2020","journal-title":"Mov. Disor."},{"issue":"6","key":"10.1016\/j.jns.2021.120078_bb0185","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s11910-013-0350-7","article-title":"Freezing of gait in Parkinson\u2019s disease: where are we now?","volume":"13","author":"Heremans","year":"2013","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"11","key":"10.1016\/j.jns.2021.120078_bb0190","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/14656566.2019.1614167","article-title":"Efficacy of istradefylline for gait disorders with freezing of gait in Parkinson\u2019s disease: a single-arm, open-label, prospective, multicenter study","volume":"20","author":"Iijima","year":"2019","journal-title":"Expert. Opin. Pharmacother."},{"issue":"23","key":"10.1016\/j.jns.2021.120078_bb0195","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1212\/01.wnl.0000313835.33830.80","article-title":"Determinants of disability and quality of life in mild to moderate Parkinson disease","volume":"70","author":"Muslimovic","year":"2008","journal-title":"Neurology."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X21027805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:58:40Z","timestamp":1758383920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X21027805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":39,"alternative-id":["S0022510X21027805"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2021.120078","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of istradefylline in patients with Parkinson's disease presenting with postural abnormalities: Results from a multicenter, prospective, and open-label exploratory study in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2021.120078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120078"}}